Survival in ALK-Positive NSCLC With Sequential Crizotinib and Ceritinib
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated With Sequential Crizotinib and Ceritinib
Clin. Cancer Res 2015 May 12;[EPub Ahead of Print], JF Gainor, DS Tan, T De Pas, BJ Solomon, A Ahmad, C Lazzari, F de Marinis, G Spitaleri, K Schultz, L Friboulet, BY Yeap, JA Engelman, AT ShawFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.